Feasibility of MicroRNAs as biomarkers for barrett's esophagus progression: A pilot cross-sectional, phase 2 biomarker study

American Journal of Gastroenterology

Volumn 106, Issue 6, 2011, Pages 1055-1063

  Bansal, Ajay ^a,b   Lee, I H ^c   Hong, X ^a   Anand, V ^c   Mathur, S C ^a   Gaddam, S ^a,b   Rastogi, A ^a   Wani, S B ^a   Gupta, N ^a   Visvanathan, M ^c   Sharma, P ^a,b   Christenson, L K ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EOSIN; HEMATOXYLIN; MICRORNA;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; FEASIBILITY STUDY; GASTROINTESTINAL DYSPLASIA; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MALE; MICROARRAY ANALYSIS; PILOT STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRECANCER; PREDICTIVE VALUE; RISK ASSESSMENT; STATISTICAL MODEL;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CROSS-OVER STUDIES; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; PILOT PROJECTS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

EID: 79957990632     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.37     Document Type: Article

References (44)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-6. (Pubitemid 40277094)
2. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009; 361: 2548-56.
3. Wani S, Mathur SC, Curvers WL et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol 2010; 8: 783-8. e2.
4. Sharma P, Falk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-72. (Pubitemid 44308164)
5. Reid BJ, Levine DS, Longton G et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify lowand high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669-76. (Pubitemid 30485000)
6. Reid BJ, Prevo LJ, Galipeau PC et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96: 2839-48. (Pubitemid 32959522)
7. Prasad GA, Bansal A, Sharma P et al. Predictors of progression in barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010; 105: 1490-502.
8. Metias SM, Lianidou E, Yousef GM. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol 2009; 62: 771-6.
9. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8. (Pubitemid 40839735)
10. Feber A, Xi L, Luketich JD et al. MicroRNA expression profiles of esophageal cancer. J Th orac Cardiovasc Surg 2008; 135: 255-60; discussion 60.
11. Kan T, Meltzer SJ. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol 2009; 9: 727-32.
12. Kan T, Sato F, Ito T et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009; 136: 1689-700.
13. Maru DM, Singh RR, Hannah C et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol 2009; 174: 1940-8.
14. Mathe EA, Nguyen GH, Bowman ED et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009; 15: 6192-200.
15. Wijnhoven BP, Hussey DJ, Watson DI et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg 2010; 97: 853-61.
16. Yang H, Gu J, Wang KK et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009; 15: 5744-52.
17. Lieberman J. Micromanaging cancer. N Engl J Med 2009; 361: 1500-1.
18. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 368-78. (Pubitemid 32378298)
19. Wani S, Choi W, Sharma P. Low-grade dysplasia in Barrett's esophagus- an innocent bystander? Pro Endoscopy 2007; 39: 643-6. (Pubitemid 47099004)
20. Bolstad BM, Irizarry RA, Astrand M et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-93. (Pubitemid 36181903)
21. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3 Article3.
22. Fiedler SD, Carletti MZ, Christenson LK. Quantitative RT-PCR methods for mature microRNA expression analysis. Methods Mol Biol 2010; 630 : 49-64.
23. Fiedler SD, Carletti MZ, Hong X et al. Hormonal regulation of MicroRNA expression in periovulatory mouse mural granulosa cells. Biol Reprod 2008; 79: 1030-7.
24. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-9. (Pubitemid 44708937)
25. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-61. (Pubitemid 32717537)
26. Dijckmeester WA, Wijnhoven BP, Watson DI et al. MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus. J Gastrointest Surg 2009; 13 : 846-53.
27. du Rieu MC, Torrisani J, Selves J et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010; 56: 603-12.
28. Ryu JK, Hong SM, Karikari CA et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010; 10: 66-73.
29. O ' Hara SP, Mott JL, Splinter PL et al. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology 2009; 136: 17-25.
30. Furuta M, Kozaki KI, Tanaka S et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-76.
31. Xia H, Qi Y, Ng SS et al. MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. Biochem Biophys Res Commun 2009; 380: 205-10.
32. Navon R, Wang H, Steinfeld I et al. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS ONE 2009; 4: e8003.
33. Brabender J, Marjoram P, Lord RV et al. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 2113-7. (Pubitemid 41603254)
34. Selaru FM, Wang S, Yin J et al. Beyond field effect: analysis of shrunken centroids in normal esophageal epithelia detects concomitant esophageal adenocarcinoma. Bioinform Biol Insights 2007; 1: 127-36.
35. Hormi-Carver K, Souza RF. Molecular markers and genetics in cancer development. Surg Oncol Clin N Am 2009; 18: 453-67.
36. Younes M, Ertan A, Lechago LV et al. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997; 42: 697-701. (Pubitemid 27196015)
37. Murray L, Sedo A, Scott M et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006; 55: 1390-7. (Pubitemid 44476779)
38. Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res 2007; 13 (2 Part 1): 659-65. (Pubitemid 46225374)
39. Kearney L, Horsley SW. Molecular cytogenetics in haematological malignancy: current technology and future prospects. Chromosoma 2005; 114: 286-94. (Pubitemid 41644376)
40. Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician 2010; 81: 1339-46.
41. Lodes MJ, Caraballo M, Suciu D et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009; 4: e6229.
42. Jung M, Schaefer A, Steiner I et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010; 56: 998-1006.
43. Szafranska AE, Davison TS, Shingara J et al. Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J Mol Diagn 2008; 10: 415-23.
44. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.